Dolutegravir combined with tenofovir alafenamide or tenofovir disoproxil fumarate had high potency and safety, with no resistance to dolutegravir after 192 weeks, but it sustained weight gain, especially among women, those with low initiation CD4 counts, and those taking tenofovir alafenamide.
All Keywords
【저자키워드】 obesity, resistance, dolutegravir, tenofovir, suppression,
【저자키워드】 obesity, resistance, dolutegravir, tenofovir, suppression,